DNA Print Genomics appointed Karen Surplus as the new chief financial officer, the company said yesterday. Her appointment is effective immediately.
She replaces current CFO Monica Tamborini, who is retiring.
Surplus ran her own financial consulting business for the past three years. She was CFO of Digital Fusion, chief accounting officer at PowerCerv and the the controller and treasurer of Progress Credit, a subsidiary of Progress Energy. She also previously served as a senior auditor with Arthur Andersen.
Surplus received a BS in Business from Kansas State Univeristy and an MBA from the University of Tampa.
Tony Marchington joined Genome Explorations as its chief operating officer, the company said on Wednesday.
He established Oxford Molecular in 1989, the first spin-out from Isis Innovation, an intellectual property company for Oxford University. The company became part of Millenium Pharmaceuticals in 2000. Prior to Oxford Molecular, he worked for ICI, now Astra Zeneca, in discovery medicinal chemistry.
Marchington received both his MA and doctorate degrees in chemistry from Oxford.
He is an adviser to the UK Government as a member of the Department of Trade and Industry's Competitiveness Advisory Group, and a member of the Pharmaceuticals Panel of the UK DTI Foresight Initiative.
Tom Humphreys will lead the research at the Center for Genomics, Proteomics, and Bioinformatics at the University of Hawaii, Manoa, said the vice-chancellor for research, Gary Ostrander, on Monday.
Effective July 1, the appointment is for three years.
Humphreys is currently a researcher in the Pacific Biosciences Research Center and a professor of cell and molecular biology at John A. Burns School of Medicine. He's been on the faculty for 34 years.
Luminex announced management changes to focus on product development and quality assurance on Monday. The appointments will be effective July 1.
For the newly created position of vice-president and chief scientific officer, the company promoted James Jacobson. Jacobson will remain chairman of the scientific advisory board.
John Carrano has been named vice-president of research and development. Carrano will join the scientific advisory board.
Oliver Meek filled the newly created post of vice-president of quality assurance and regulatory affairs.
Morrie Ruffin, executive vice-president for emerging companies and business development, will leave the Biotechnology Industry Organization today to become CEO of consultancy LifeTech Innovations, said Jim Greenwood, president and chief executive officer, on Tuesday.
Ruffin will continue consulting for BIO, said Greenwood.
Alan Eisenberg, BIO's executive vice-president for advocacy, operations, & communications, will assume Ruffin's responsibilities.
Before joining BIO, Eisenberg served as a senior advisor on health and economics policy when Greenwood was in Congress. He was also a health policy advisor for the Senate Health, Education, Labor and Pensions Subcommittee on Public Health and a legislative assistant for Arizona's Congressman John Shadegg.
Eisenberg holds a Master of Public Policy degree from Harvard University and an MS in finance from George Washington University.
The Howard Hughes Medical Institute announced on Tuesday the first 13 awardees for the Physician-Scientist Early Career Award program. Vamsi Mootha and Atul Butte are amongst the winners to receive $150,000 over three years to cover direct research expenses.
Mootha is an assistant professor of medicine and systems biology at Harvard Medical School and the Center for Human Genetic Research at Massachusetts General Hospital. He has been named a MacArthur Foundation fellow.
Atul Butte is an assistant professor of medical informatics and pediatrics at Stanford University School of Medicine.
Essam Sheta has been named to the review panel for the American Institute of Biological Sciences to review grant proposals on Parkinson's disease, Power3 Medical Products said Tuesday.
Director of biochemistry of Power3 since 2001, Sheta worked in Egypt's Alexandria University, Washington State Univeristy, the University of Texas Medical Center at San Antonio and the University of Virginia.
Alnylam Pharmaceuticals elected Judy Lieberman to its scientific advisory board, the company said Tuesday.
A senior investigator at the CBR Institute for Biomedical Research, Lieberman is a professor of pediatrics and the director of the AIDS division at Harvard Medical School.
She worked at the Institute for Advanced Study in Princeton University and the Fermi National Accelerator Laboratory.
She received her B.A. from Radcliffe College, her PhD in physics from Rockefeller University, and an MD from the joint Harvard-MIT Program in Health, Science, and Technology. She completed her postdoctoral work at Massachusetts Institute of Technology.
Jack Goldstein has joined Illumina's board of directors, the company said Tuesday.
Goldstein was most recently president and chief operating officer of Chiron until its acquisition by Novartis in April. He spent two years as a general partner at Windamere Venture Partners and four years at Applied Imaging, first as president and chief executive officer and then later as chairman.
He spent over ten years at Ortho Diagnostic Systems, a Johnson & Johnson company, four of them as president. He was also vice-president of research and development at Baxter Healthcare.
Goldstein earned a B.A. in biology from Rider University, and an MS in immunology and PhD in microbiology from St. John's University.
He currently sits on the board of directors of Orasure Technologies.
Joseph Vallner joined Lumera's board of directors, the company said Wednesday at its annual shareholder meeting.
Vallner is the president and chief operating officer of Cell Genesys. Prior to Cell Genesys, he was with Sequus Pharmaceuticals for seven years. Prior to Sequus, he held various positions with Syntex and G.D. Searle.
Vallner was an associate professor of pharmaceutics at University of Georgia. He received his PhD in pharmaceutics, an MS in physical chemistry and a BS in pharmacy from University of Wisconsin, Madison.
He serves as a board member of the California Healthcare Institute.
Decode Genetics appointed Birgit Norinder to its board of directors, the company said Wednesday. The appointment is effective immediately.
Norinder held senior clinical development and regulatory affairs positions in Europe and US at Pfizer, Astra, Glaxo and Pharmacia & Upjohn. She was chief executive officer and chairman of UK-based Prolifix until its merger with TopoTarget in 2002.
She currently serves on the boards of Antisoma, Artimplant, Photocure, and Biolipox. She is chairman of the board for Betagenon.
Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected]to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.